RCE 8/29/05

AMENDMENTS

Please amend the following claims:

Claim 1 (Currently amended) A pharmaceutical composition comprising:

a) a psychotropic, neurotropic or neurological drug, or an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug, wherein the drug is L-dopa, hydroxytryptamine, amantadine, benztropine, bromocryptine, diphenhydramine, levadopa, pergolid, trihexphenidyl, ethosuximide, valproic acid, carbamazepine, 10-hydroxycarbamazepine, 11-hydroxycarbamazepine, primidone, gabapentin, lamotrigine, felbamate, paramethadione, trimethadione, phenothiazine, thioxantheme, clozapine, haldoperidol, loxapine, a benzodiazapene antidepressants of the norepinephrine reuptake inhibitor type, a monoamine oxidase inhibitor, carotene, glutathione, N-acetylcysteine, methotrexate, azidothymidine, dideoxyinosine, dideoxycytosine, acyclovir, or gancyclovir;

Lease do not enter this Amendment SAD 8/29/05

b) ~~an amino acid or amino acid derivative specifically transported into a physiologically protected site, wherein the amino acid or derivative thereof is~~ 5-hydroxytryptophan, serotonin, or melatonin; and

c) a spacer having two linker functional groups and

~~d) a spacer,~~

wherein ~~the spacer has a first end and a second end and~~ wherein the amino acid or amino acid derivative is attached to the ~~first end of the~~ spacer through a first linker functional group and the drug is attached to the ~~second end of the~~ spacer through a second linker functional group.

Claim 2 (cancelled)

Claim 3 (Currently amended). A pharmaceutical composition according to Claim 1 wherein the spacer allows the drug to act without being released at an intracellular site and wherein the first linker functional group ~~attached to the first end of the spacer~~ is strong and the second linker functional group ~~attached to the second end of the spacer~~ is weak.